Nature Reviews Clinical Oncology
Papers 3401
1 page of 341 pages (3,401 results)
#1Francesc Bosch (University of Barcelona)H-Index: 1
#2Riccardo Dalla-Favera (Columbia University)H-Index: 107
Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature CD5+CD23+ B cells in the peripheral blood, secondary lymphoid tissues and bone marrow. CLL is an incurable disease with a heterogeneous clinical course, for which the treatment decision still relies on conventional parameters (such as clinical stage and lymphocyte doubling time). During the past 5 years, relevant advanc...
#1John D. Cramer (WSU: Wayne State University)H-Index: 1
#2Barbara Burtness (Yale University)H-Index: 42
Last.Robert L. Ferris (University of Pittsburgh)H-Index: 66
view all 4 authors...
Head and neck cancers are a heterogeneous collection of malignancies of the upper aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the changing therapeutic landscape of head and neck squamous cell carcinomas (HNSCCs) that can arise in the oral cavity, oropharynx, hypopharynx and larynx. We highlight developments in surgical and non-surgical therapies (mainly involving the combination of radiotherapy and chemotherapy), outlining how these treatments are bein...
#1Jordan A. Torok (Duke University)H-Index: 4
#2Joseph K. Salama (Duke University)H-Index: 35
In the past few years, efforts have been made to combine two approaches — immune-checkpoint inhibition and locally ablative radiation therapy — to treat patients with metastatic non-small-cell lung cancer. Herein we discuss the implications of two studies that support the existence of a systemic therapy augmented by radiotherapy (STAR) effect in this setting.
#1Kaustav Bera (Case Western Reserve University)H-Index: 3
#2Kurt A. Schalper (Yale University)H-Index: 29
Last.Anant Madabhushi (Case Western Reserve University)H-Index: 43
view all 5 authors...
In the past decade, advances in precision oncology have resulted in an increased demand for predictive assays that enable the selection and stratification of patients for treatment. The enormous divergence of signalling and transcriptional networks mediating the crosstalk between cancer, stromal and immune cells complicates the development of functionally relevant biomarkers based on a single gene or protein. However, the result of these complex processes can be uniquely captured in the morphome...